RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RNXT RenovoRx Inc

Trading 06-06 15:44:03 EDT

1.06

-0.02

-1.85%

High1.08	Low1.04	Vol61.46K
Open1.08	D1 Closing1.08	Amplitude3.69%
Mkt Cap25.39M	Tradable Cap24.90M	Total Shares23.95M
T/O64.69K	T/O Rate0.26%	Tradable Shares23.49M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"RNXT","market":"US","secType":"STK","nameCN":"RenovoRx Inc","latestPrice":1.06,"timestamp":1717702888633,"preClose":1.08,"halted":0,"volume":61463,"delay":0,"floatShares":23488855,"shares":23951825,"eps":-0.684897,"marketStatus":"Trading","change":-0.02,"latestTime":"06-06 15:44:03 EDT","open":1.08,"high":1.08,"low":1.0401,"amount":64690.422130000006,"amplitude":0.036944,"askPrice":1.07,"askSize":700,"bidPrice":1.04,"bidSize":1279,"shortable":3,"etf":0,"ttmEps":-0.684897,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1717704000000},"marketStatusCode":2,"adr":0,"listingDate":1629950400000,"exchange":"NASDAQ","adjPreClose":1.08,"preHourTrading":{"tag":"盘前","latestPrice":1.04,"preClose":1.08,"latestTime":"09:15 EDT","volume":1534,"amount":1594.2101136,"timestamp":1717679703417},"postHourTrading":{"tag":"盘后","latestPrice":1.07,"preClose":1.07,"latestTime":"16:00 EDT","volume":152,"amount":162.64,"timestamp":1717617625416},"volumeRatio":1.764053},"requestUrl":"/m/hq/s/RNXT/","defaultTab":"news","newsList":[{"id":"2439497336","title":"RenovoRx CEO Issues Update Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2439497336","media":"Business Wire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2439497336?lang=en_us&edition=fundamental","pubTime":"2024-05-30 20:30","pubTimestamp":1717072200,"startTime":"0","endTime":"0","summary":"With $17.2 million in gross proceeds raised since the beginning of 2024, RenovoRx is well positioned to advance its pivotal Phase III clinical trial, expand development pipeline into additional cancer indications and explore new commercial business development opportunities with its therapeutic technologies. LOS ALTOS, Calif., May 30, 2024----RenovoRx, Inc.  , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief Executive Officer, Shaun Bagai.In March, RenovoRx promoted Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak to Principal Accounting Officer. These promotions reflect our commitment to assembling a dynamic team poised to continue to lead a successful clinical pathway for our proprietary therapy platform. We have streamlined our team,","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/yEk73CFGCI9s5SvNfpUsLA--~B/aD0xNjA0O3c9NDE0NjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/5f2f6d839d86ed0a7a75594754ef0a06","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/yEk73CFGCI9s5SvNfpUsLA--~B/aD0xNjA0O3c9NDE0NjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/5f2f6d839d86ed0a7a75594754ef0a06"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/renovorx-ceo-issues-letter-shareholders-123000224.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","RNXT","BK4539"],"gpt_icon":0},{"id":"2437483754","title":"Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=2437483754","media":"Business Wire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2437483754?lang=en_us&edition=fundamental","pubTime":"2024-05-21 21:00","pubTimestamp":1716296400,"startTime":"0","endTime":"0","summary":"Data shows that the Trans-Arterial Micro-Perfusion  platform increases intra-arterial pressure, improving drug delivery with 100-fold increase local tissue concentration of the therapy. TAMP offers the potential to increase efficacy, improve safety and widen therapeutic window of drugs or other agents. Currently, most cancer patients with solid tumors receive chemotherapy intravenously, meaning it is introduced systemically into the entire body and causes well known adverse side effects. RenovoRx’s patented TAMP therapy platform is designed to bypass traditional systemic delivery methods and provide precise delivery to bathe the target solid tumor in chemotherapy. This precise delivery also creates the potential to minimize a therapy’s systemic toxicities.\"TAMP has the potential to provide a valuable treatment option to patients who have been diagnosed with solid tumors that may be difficult-to-treat,\" said Dr. Farsad. \"The study shows a possible mechanism for how TAMP can increase loc","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/oIMkoB5CVVZgkYQ5cJyBsw--~B/aD0xNjA0O3c9NDE0NjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/56741286cf115df4065959f3ee244e79","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/oIMkoB5CVVZgkYQ5cJyBsw--~B/aD0xNjA0O3c9NDE0NjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/56741286cf115df4065959f3ee244e79"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/publication-results-pre-clinical-studies-130000365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RNXT","BK4539","BK4139"],"gpt_icon":0},{"id":"2435193395","title":"RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2435193395","media":"Business Wire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435193395?lang=en_us&edition=fundamental","pubTime":"2024-05-14 21:00","pubTimestamp":1715691600,"startTime":"0","endTime":"0","summary":"LOS ALTOS, Calif., May 14, 2024----RenovoRx, Inc.  , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, Chief Executive Officer, will participate in a fireside chat at Alliance Global Partners  Virtual Healthcare Company Showcase hosted by Scott Henry, Managing Director and Healthcare Analyst at A.G.P. The event will be held on Tuesday, May 21, 2024.Mr. Bagai will discuss recent corporate milestones, including the completion of private placements in January and April 2024 in which RenovoRx raised $17.2 million in total gross proceeds. The financing provides RenovoRx sufficient funding to advance pivotal Phase III TIGeR-PaC clinical trial, expand development pipeline into additional cancer indications and continue the Company’s ongoing exploration of new commercial business development opportunities with its therapeutic technologies.The TIGeR-PaC study is evaluating the Compa","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.SEA7EQxRYg2aWGQLlDj2g--~B/aD0xNjA0O3c9NDE0NjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/d827710eb1fa694746e7763185acdd3f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.SEA7EQxRYg2aWGQLlDj2g--~B/aD0xNjA0O3c9NDE0NjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/d827710eb1fa694746e7763185acdd3f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/renovorx-participate-fireside-chat-g-130000788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4137","BK4539","RNXT","HCSG"],"gpt_icon":0},{"id":"2435784013","title":"RenovoRx Inc reports results for the quarter ended in January - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2435784013","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435784013?lang=en_us&edition=fundamental","pubTime":"2024-05-13 21:31","pubTimestamp":1715607114,"startTime":"0","endTime":"0","summary":"* RenovoRx Inc    reported a quarterly adjusted loss of 7 cents per share for the quarter ended in January, higher than the same quarter last year, when the company reported EPS of -36 cents.  The mea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT"],"gpt_icon":0},{"id":"2434691384","title":"Biopharmaceutical Challenger Renovorx: Navigating Uncertainty and Financial Risks in Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2434691384","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434691384?lang=en_us&edition=fundamental","pubTime":"2024-05-12 14:00","pubTimestamp":1715493639,"startTime":"0","endTime":"0","summary":"Renovorx, Inc. (RNXT) has disclosed a new risk, in the Accounting & Financial Operations category. Renovorx, Inc., a clinical-stage biopharmaceutic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biopharmaceutical-challenger-renovorx-navigating-uncertainty-and-financial-risks-in-drug-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biopharmaceutical-challenger-renovorx-navigating-uncertainty-and-financial-risks-in-drug-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","RNXT"],"gpt_icon":0},{"id":"2434856705","title":"RenovoRx Inc    expected to post a loss of 14 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2434856705","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434856705?lang=en_us&edition=fundamental","pubTime":"2024-05-10 21:03","pubTimestamp":1715346187,"startTime":"0","endTime":"0","summary":"* RenovoRx Inc     is expected to show no change in quarterly revenue when it reports  results on May 13 (estimated) for the period ending March 31 2024   *    * LSEG's mean analyst estimate for Renov","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT"],"gpt_icon":0},{"id":"2428593044","title":"RenovoRx regains compliance with Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2428593044","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2428593044?lang=en_us&edition=fundamental","pubTime":"2024-04-18 20:41","pubTimestamp":1713444107,"startTime":"0","endTime":"0","summary":"RenovoRx  said it has received written confirmation from the Nasdaq that the company has regained compliance with the $2.5 million minimum stockholders’ equity requirement in Nasdaq listing rule.The company will also not require any ongoing Nasdaq hearings panel monitor.More on RenovoRx  RenovoRx closes $6.1M private placement Seeking Alpha’s Quant Rating on RenovoRx","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4090957-renovorx-regains-compliance-with-nasdaq","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["MNQmain","PSQ","NDAQ","BK4112","NQmain","QQQ","SQQQ","QID",".IXIC","LU2210150020.SGD","BK4539","LU2210149790.SGD","LU2095319765.USD","QLD","BK4588","TQQQ","BK4139","BK4585","RNXT"],"gpt_icon":0},{"id":"2425299971","title":"BRIEF-RenovoRx Announces $11.1 Mln At Market Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2425299971","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2425299971?lang=en_us&edition=fundamental","pubTime":"2024-04-08 20:39","pubTimestamp":1712579940,"startTime":"0","endTime":"0","summary":"April 8  - RenovoRx Inc   :   * RENOVORX ANNOUNCES $11.1 MILLION AT MARKET PRIVATE PLACEMENT   * RENOVORX INC - CASH POSITION NOW EXPECTED TO FUND CURRENT OPERATING PLAN INTO 2026   * RENOVORX INC - PROCEEDS FROM FINANCING ARE ALSO EXPECTED TO ENABLE EXPANSION OF TAMP CLINICAL DEVELOPMENT PIPELINE INTO ADDITIONAL CANCER INDICATIONSSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNXT","BK4539"],"gpt_icon":0},{"id":"2425997447","title":"RenovoRx Announces $11.1 Million at Market Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2425997447","media":"Business Wire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2425997447?lang=en_us&edition=fundamental","pubTime":"2024-04-08 20:30","pubTimestamp":1712579400,"startTime":"0","endTime":"0","summary":"Cash position now expected to fund current operating plan into 2026. Financing provides cash runway to advance the ongoing pivotal Phase III TIGeR-PaC trial through the second interim readout and towards completion of the trial. Financing also enables the expansion of RenovoRx’s TAMP  clinical development pipeline into additional cancer indications. In connection with the private placement, the Company will issue 7,912,364 shares of common stock, five-year Series A Warrants to purchase an aggregate of up to 7,912,364 shares of common stock, and two-year Series B Warrants, to purchase an aggregate of up to 3,956,182 shares of common stock, with the Series A Warrants and Series B Warrants together constituting 150% warrant coverage. Investors will pay a purchase price of $1.4075 for each share and associated Series A Warrant and Series B Warrant, with such price being at the market for purposes of Nasdaq Stock Market rules. The Series A Warrants and Series B Warrants are each exercisable","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/gs2cFFuPgCHiGDeYoa6OdA--~B/aD0yNTE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/5ea236c25b1076d61eea2f7798ece8e0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/gs2cFFuPgCHiGDeYoa6OdA--~B/aD0yNTE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/5ea236c25b1076d61eea2f7798ece8e0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/renovorx-announces-11-1-million-123000209.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","RNXT","BK4139"],"gpt_icon":0},{"id":"2424070812","title":"RenovoRx Inc reports results for the quarter ended in December - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2424070812","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2424070812?lang=en_us&edition=fundamental","pubTime":"2024-04-02 06:14","pubTimestamp":1712009670,"startTime":"0","endTime":"0","summary":"* RenovoRx Inc    reported a quarterly adjusted loss of 31 cents per share for the quarter ended in December, lower than the same quarter last year, when the company reported EPS of -23 cents.  The me","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT"],"gpt_icon":0},{"id":"2418534809","title":"RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2418534809","media":"Business Wire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2418534809?lang=en_us&edition=fundamental","pubTime":"2024-03-12 21:00","pubTimestamp":1710248400,"startTime":"0","endTime":"0","summary":"LOS ALTOS, Calif., March 12, 2024----RenovoRx, Inc.  , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai, RenovoRx’s Chief Executive Officer, will present at the 36th Annual ROTH Conference to be held March 17-19, 2024 in Dana Point, CA.Mr. Bagai will meet with investors and participate in a fireside chat hosted by Jonathan Aschoff, Senior Research Analyst at Roth MKM on Tuesday, March 19, 2024 at 10:00 am PT.Mr. Bagai will discuss recent Company milestones, including an initial positive interim analysis on the Company’s pivotal Phase III TIGeR-PaC clinical trial. The study is evaluating the Company’s lead product candidate, RenovoGem, and proprietary Trans-Arterial Micro-Perfusion  therapy platform for the treatment of locally advanced pancreatic cancer.RenovoRx is committed to transforming the lives of patients by delivering innovative solutions to change the current parad","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rr.ZHybr4Wtare1kt.asUg--~B/aD0yNTE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/739beb12e10532dc08fe21100a401ea0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rr.ZHybr4Wtare1kt.asUg--~B/aD0yNTE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/739beb12e10532dc08fe21100a401ea0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/renovorx-present-36th-annual-roth-130000743.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RNXT","BK4139","BK4539","ROTH"],"gpt_icon":0},{"id":"2418781248","title":"RenovoRx promotes Leesa Gentry to chief clinical officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2418781248","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2418781248?lang=en_us&edition=fundamental","pubTime":"2024-03-09 05:33","pubTimestamp":1709933617,"startTime":"0","endTime":"0","summary":"RenovoRx  Friday announced key leadership promotions of Leesa Gentry to chief clinical officer and Ronald B. Kocak, CPA to principal accounting officer.More on RenovoRx  RenovoRx closes $6.1M private placement Seeking Alpha’s Quant Rating on RenovoRx Historical earnings data for RenovoRx Financial information for RenovoRx","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4077768-renovorx-promotes-leesa-gentry-to-chief-clinical-officer","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["NQmain","QID","QQQ","TQQQ",".IXIC","QLD","RNXT","MNQmain","BK4139","SQQQ","BK4539","PSQ"],"gpt_icon":0},{"id":"2418909080","title":"RenovoRx Highlights Key Leadership Promotions","url":"https://stock-news.laohu8.com/highlight/detail?id=2418909080","media":"StreetInsider","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2418909080?lang=en_us&edition=fundamental","pubTime":"2024-03-09 05:05","pubTimestamp":1709931900,"startTime":"0","endTime":"0","summary":"Company has promoted Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak to Principal Accounting Officer. RenovoRx, Inc.  , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today highlighted the recent key leadership promotions of Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak, CPA to Principal Accounting Officer.Mr. Kocak has been promoted to the position of Principal Accounting Officer and will retain his roles as Vice President and Controller of RenovoRx. He joined the Company in October 2021 and is a seasoned financial reporting and accounting professional with extensive public and private company experience in the life sciences industry. Mr. Kocak was instrumental in the recent completion of a $6.1 million private placement that extended RenovoRx’s cash runway to support its clinical program initiatives. In this new leadership role, Mr. Kocak will oversee all financial management, r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22907233","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["BK4539","BK4139","RNXT"],"gpt_icon":0},{"id":"2414809070","title":"RenovoRx Inc    expected to post a loss of 30 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2414809070","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2414809070?lang=en_us&edition=fundamental","pubTime":"2024-02-27 23:45","pubTimestamp":1709048739,"startTime":"0","endTime":"0","summary":"* RenovoRx Inc     is expected to show no change in quarterly revenue when it reports  results on February 29 (estimated) for the period ending December 31 2023   *    * LSEG's mean analyst estimate f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT"],"gpt_icon":0},{"id":"2413047706","title":"RenovoRx Struggles to Avoid Nasdaq Delisting Amid Leadership Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2413047706","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2413047706?lang=en_us&edition=fundamental","pubTime":"2024-02-24 23:15","pubTimestamp":1708787708,"startTime":"0","endTime":"0","summary":"RenovoRx (RNXT) has released an update. RenovoRx, Inc. is on the brink of being delisted from The Nasdaq Capital Market for failing to meet the min...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/renovorx-struggles-to-avoid-nasdaq-delisting-amid-leadership-changes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/renovorx-struggles-to-avoid-nasdaq-delisting-amid-leadership-changes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NQmain",".IXIC","BK4112","QLD","LU2210150020.SGD","LU2095319765.USD","BK4539","BK4585","LU2210149790.SGD","QID","BK4588","QQQ","TQQQ","RNXT","BK4139","NDAQ","MNQmain","SQQQ","PSQ"],"gpt_icon":0},{"id":"2413785743","title":"BRIEF-Renovorx Says On February 21, Co Got Notice From Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2413785743","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2413785743?lang=en_us&edition=fundamental","pubTime":"2024-02-24 07:48","pubTimestamp":1708732082,"startTime":"0","endTime":"0","summary":"Feb 23 (Reuters) - RenovoRx Inc   :   * RENOVORX INC - ON FEBRUARY 21, CO GOT NOTICE FROM NASDAQ THAT CO HAD, AS OF DATE OF NOTICE, FAILED TO MEET MINIMUM STOCKHOLDERS' EQUITY REQUIREMENTSource text for Eikon:    Further company coverage:    ((reuters.briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4539","QID","QQQ","LU2095319765.USD","NQmain","SQQQ","QLD","LU2210149790.SGD","PSQ","BK4112","BK4585","TQQQ",".IXIC","BK4588","BK4139","NDAQ","RNXT","MNQmain"],"gpt_icon":0},{"id":"2410099820","title":"BRIEF-Renovorx Says James Ahlers Provided Notice To Co Of His Resignation As Chief Financial Officer, Effective Immediately","url":"https://stock-news.laohu8.com/highlight/detail?id=2410099820","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2410099820?lang=en_us&edition=fundamental","pubTime":"2024-02-10 06:16","pubTimestamp":1707517015,"startTime":"0","endTime":"0","summary":"Feb 9 (Reuters) - RenovoRx Inc   :   * RENOVORX INC-  ON FEB 5 JAMES AHLERS PROVIDED NOTICE TO CO OF HIS RESIGNATION AS COMPANY'S CHIEF FINANCIAL OFFICER, EFFECTIVE IMMEDIATELYSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT","BK4539","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.renovorx.com","stockEarnings":[{"period":"1week","weight":-0.1301},{"period":"1month","weight":-0.1508},{"period":"3month","weight":-0.3886},{"period":"6month","weight":0.7261},{"period":"1year","weight":-0.4368},{"period":"ytd","weight":-0.5328}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.035},{"period":"3month","weight":0.0386},{"period":"6month","weight":0.1618},{"period":"1year","weight":0.2491},{"period":"ytd","weight":0.1249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. The company was founded in 2009 and is headquartered in Los Altos, California.","exchange":"NASDAQ","name":"RenovoRx Inc","nameEN":"RenovoRx Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.23.1","shortVersion":"4.23.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest RenovoRx Inc(RNXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"RenovoRx Inc,RNXT,RenovoRx Inc股票,RenovoRx Inc股票老虎,RenovoRx Inc股票老虎国际,RenovoRx Inc行情,RenovoRx Inc股票行情,RenovoRx Inc股价,RenovoRx Inc股市,RenovoRx Inc股票价格,RenovoRx Inc股票交易,RenovoRx Inc股票购买,RenovoRx Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest RenovoRx Inc(RNXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction